First quarter 2025
First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Thursday April 24, 2025
13:00 - 14:30 CEST (7:00am – 8:30am EDT)
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
We’re off to a great start in 2025. Our investment in innovation and focus on pipeline value is paying off, as we see launches of new medicines and vaccines strongly contributing to our sales growth.
Paul Hudson
Chief Executive Officer